Event

Juergen Behr

MD, PhD
Comprehensive Pneumology Center;Department of Internal Medicine V, LMU and Asklepios Fachkliniken Gauting, Comprehensive Pneumology ;University of Munich, Comprehensive Pneumology Center;University of

Monica Bengus

MD
F. Hoffmann-La Roche Ltd.;F. Hoffmann-La Roche, Ltd.

Klaus-Uwe Kirchgaessler

MD
F. Hoffmann-La Roche Ltd.;F. Hoffmann-La Roche, Ltd.

Sergio Harari

MD
U.O. di Pneumologia e Terapia Semi-Intensiva Respiratoria, Servizio di Fisiopatologia Respiratoria e

Wim Wuyts

MD, PhD
KU Leuven;University Hospitals Leuven;University of Leuven

Steven Nathan

MD
Inova;Inova Fairfax Hosp;Inova Fairfax Hospital;Inova Heart and Vascular Institute, Inova Fairfax Hospital

Frank Gilberg

PhD
F. Hoffmann-La Roche Ltd.;F. Hoffmann-La Roche, Ltd.

Athol Wells

M.D.
Interstitial Lung Disease Unit, Royal Brompton Hospital;Royal Brompton and Harefield NHS Foundation Trust, and National Heart and Lung Institute, Imperial C;Royal Brompton Hospital

Baseline Characteristics from a Pre-Specified Interim Analysis of a Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial of Sildenafil Added to Pirfenidone in Patients with Advanced Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension